Select Medical (NYSE:SEM) leaves NYSE after $3.9B buyout, one-cent deal spread
Select Medical Holdings Corporation (NYSE:SEM) has delisted from the NYSE after a $3.9 billion cash buyout, with its shares last trading at $16.51, just one cent above the $16.50 per share offer. The merger, led by Executive Chairman Robert A. Ortenzio and other partners, closed on July 1st, leading to SEM's removal from the S&P SmallCap 600. Goldman Sachs & Co. LLC advised that the $16.50 cash offer was fair to shareholders, while the company maintained its 2026 guidance prior to the deal.
Select Medical (NYSE: SEM) vice chair exits common stock in merger
Select Medical Holdings Corp vice chairman David S. Chernow reported significant changes to his common stock holdings due to a merger. A large block of 656,823 shares was converted to cash, while restricted shares were exchanged for interests in Stallion Group Parent, LP, and others were surrendered for tax obligations. Following these transactions, Chernow no longer directly holds the issuer's common stock, reflecting a complete exit tied to the merger agreement.
[Form 4] SELECT MEDICAL HOLDINGS CORP Insider Trading Activity
Select Medical Holdings Corp director Katherine R. Davisson disposed of 60,035 shares of common stock at $16.50 per share due to a merger agreement. The transaction, filed with a Form 4, resulted in her holding no remaining shares, as all her shares, including previously unvested restricted shares, were converted into cash at the merger's effective time.
Director Thomas Scully exits Select Medical (SEM) as all shares convert to $16.50 cash in merger
Select Medical Holdings director Thomas Scully disposed of his entire holding of 103,424 common shares at $16.50 per share due to a cash merger. This transaction, revealed in a Form 4 filing, converted all his equity, including unvested restricted shares, into cash, leaving him with zero shares. The disposition was a standard outcome of the merger agreement, not a discretionary trade.
Merger shifts 135,084 Select Medical (SEM) shares into parent LP
Select Medical Holdings EVP, John Tyler Hollenbach, restructured 135,084 common shares of SEM through a merger agreement. These shares were contributed to Stallion Intermediate Corporation and subsequently exchanged for interests in Stallion Group Parent, LP, rather than being sold in the open market. Following this transaction, Hollenbach directly holds zero Select Medical common shares.
Select Medical (NYSE: SEM) chairman rolls over large stake, cashes out 279,000 shares
Select Medical's (NYSE: SEM) Executive Chairman, Robert A. Ortenzio, and related family trusts restructured their considerable holdings as part of the company's merger with Stallion Intermediate Corporation. Millions of shares were rolled over into the new ownership structure, Stallion Group Parent, LP, indicating an equity exchange rather than open-market sales. Additionally, 279,000 shares held by the Robert A. Ortenzio Descendants Trust were converted into a cash payout of $16.50 per share at the time of the merger.
Select Medical (SEM) director exits 80,035 shares for $16.50 in cash merger
Select Medical Holdings Corp director Thomas Daniel disposed of 80,035 shares of his common stock for $16.50 per share in connection with the company's merger. This transaction, which included previously unvested restricted shares that fully vested, resulted in him holding zero shares after the merger. The disposition was part of an Agreement and Plan of Merger where all shares were converted into cash consideration.
Merger shifts 610K Select Medical (SEM) shares into Stallion parent LP
Select Medical Holdings director Russell L. Carson restructured 610,035 shares of Common Stock due to a merger involving Stallion Intermediate Corporation and Stallion MergerSub Corporation. These shares, including 14,035 restricted shares, were contributed to the new parent entity. Carson received equivalent parent common shares, which were then exchanged for interests in Stallion Group Parent, LP, resulting in zero direct ownership of Select Medical Common Stock.
Director’s 36K Select Medical (SEM) shares converted to $16.50 cash
Select Medical Holdings Corp (SEM) director Marilyn B. Tavenner disposed of 36,035 shares in a merger-related conversion, receiving $16.50 per share in cash, totaling $595,000. This transaction was part of an Agreement and Plan of Merger entered into on March 2, 2026, where all her shares, including previously unvested restricted shares, were converted to cash, leaving her with no direct holdings in the company. The merger was with Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Merger pays Select Medical (NYSE: SEM) director $16.50 per share
Select Medical Holdings Corp director James S. Ely III disposed of 161,674 shares of common stock as part of a company merger, receiving $16.50 per share in cash. This transaction, which included previously unvested restricted shares that vested immediately prior to the merger, resulted in him holding zero shares, demonstrating the cash-based acquisition of his equity. The merger consideration was set at $16.50 cash per share for all common stock, as detailed in the Form 4 filing.
Select Medical (NYSE: SEM) completes $16.50 cash merger and delists shares
Select Medical Holdings Corporation has completed its cash merger, with each common share converted into $16.50 in cash. Following the transaction, the company's stock was delisted from the NYSE, effective July 1, 2026. Key insiders, including Robert A. Ortenzio and Martin F. Jackson, now report beneficial ownership of 0 shares, marking an exit filing for their equity stake in the formerly public company.
Select Medical Holdings Corporation Acquired By Consortium Led By Robert A. Ortenzio, Martin F. Jackson, And Wcas
Select Medical Holdings Corporation has been acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. This news was reported by Reuters. Further details are concise, indicating the transaction is complete.
Select Medical Holdings Corporation(NYSE:SEM) dropped from S&P Health Care Services Select Industry Index
Select Medical Holdings Corporation (NYSE: SEM) has been removed from the S&P Health Care Services Select Industry Index. This news follows several other recent index removals for the company, including the S&P Global BMI Index, S&P 1000, S&P TMI Index, S&P 600 Health Care, S&P 600, and S&P Composite 1500, indicating a significant change in its index representation. The announcements coincide with the completion of a $4 billion buyout of Select Medical by an executive-led consortium and stockholder approval for the acquisition.
Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical (NYSE: SEM) has completed its acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe for $16.50 per share, valuing the company at $3.9 billion. This price represents an 18% premium to the unaffected share price and a 25% premium to the 90-day volume-weighted average price as of November 24, 2025. Effective July 1, 2026, Select Medical will be delisted from the NYSE, with current leadership remaining in place.
Select Medical completes $3.9 billion management buyout
Select Medical Holdings Corporation has completed its acquisition by a consortium led by Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and Welsh, Carson, Anderson & Stowe for approximately $3.9 billion. The transaction, at $16.50 per share, represents an 18% premium over the stock's price on November 24, 2025. With the Certificate of Merger effective July 1, 2026, Select Medical's common stock will cease trading and be delisted from the NYSE, with current officers continuing in their roles.
Select Medical acquired for $3.9B at $16.50/share, delisting from NYSE July 1, 2026
Select Medical Holdings Corporation has been acquired for approximately $3.9 billion at $16.50 per share by a consortium led by its Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and private equity firm WCAS. The acquisition, which represents a significant premium over recent share prices, was approved by shareholders. Select Medical will be delisted from the NYSE on July 1, 2026, with current leadership remaining in place.
Press Release: Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical Holdings Corporation announced that its stockholders have approved the acquisition of the company by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. Stockholders voted to adopt the merger agreement at a special meeting. The transaction is anticipated to close promptly following the satisfaction of remaining closing conditions.
Price to sales forward of Select Medical Holdings Corporation – LS:A0Q9RF
The article provides financial data for Select Medical Holdings Corporation (A0Q9RF) on TradingView, specifically focusing on its forward price-to-sales ratio. It lists the company's market status as closed and indicates no recent trades. The content primarily consists of navigational elements and legal disclaimers rather than an in-depth analysis of the financial metric.
Price to earnings forward of Select Medical Holdings Corporation – NYSE:SEM
This page provides financial information for Select Medical Holdings Corporation (NYSE: SEM), specifically focusing on its forward Price to Earnings (P/E) ratio. It notes that the market was closed at the time of viewing, with no trades, and offers various financial metrics and resources for the company.
Select Medical Holdings Corporation Actuals & Estimates (NYSE:SEM)
This article provides an overview of Select Medical Holdings Corporation (NYSE:SEM) financials, stock performance, and analyst expectations. It covers current stock price, historical highs and lows, market capitalization, volatility, and details on earnings, revenue, dividends, and employee count. The piece also includes frequently asked questions about investing in SEM stock.
Select Medical merger approved by shareholders, expected to close mid-2026
Select Medical Holdings Corporation's merger agreement with a consortium led by its Executive Chairman and WCAS has been approved by over 79% of shareholders. The deal, pending regulatory approval, is anticipated to close by mid-2026, transitioning the major recovery and rehabilitation hospital operator into new ownership. This change is also prompting Select Medical's removal from the S&P SmallCap 600 index.
Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical Holdings Corporation announced that its stockholders approved the acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS). The approval occurred at a special meeting on June 26, 2026, with over 79.88% of outstanding shares and 76.64% of unaffiliated shares voting in favor. The closing of the merger is expected mid-2026, subject to the terms and conditions detailed in the Definitive Proxy Statement filed with the SEC.
Select Medical Holdings Corporation announced that its shareholders have officially approved the tender offer initiated by a consortium composed of company executives Robert A. Ortenzio, Martin F. Jackson, and the private equity firm Welsh, Carson, Anders
Select Medical Holdings Corporation's shareholders have approved a tender offer from a consortium including company executives Robert A. Ortenzio, Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe (WCAS). This approval signifies a move towards privatization for the healthcare service provider, after which Select Medical will be delisted from the public market.
Press Release: Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical Holdings Corporation announced that its stockholders have approved the acquisition of the company by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. Stockholders voted in favor of the merger agreement and the merger at a special meeting. This approval moves the company closer to completing the acquisition.
Select Medical Stockholders Approve Acquisition by Investor Consortium
Select Medical Holdings Corporation stockholders have approved the company's acquisition by an investor consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe. This vote, which occurred on June 26, 2026, will transition the healthcare provider into a privately held entity. The transaction involves the investor group acquiring all outstanding common stock, with finalization subject to regulatory requirements.
Select Medical Holdings Corporation Announces Stockholder Approval Of Acquisition By Consortium Led By Robert A. Ortenzio, Martin F. Jackson, And Wcas
Select Medical Holdings Corporation announced that its stockholders have approved the acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. This news, reported by Refinitiv, indicates a significant corporate action for Select Medical Holdings.
Select Medical Stockholders Approve Acquisition by Ortenzio, Jackson, and WCAS Consortium
Select Medical Holdings Corporation (NYSE: SEM) shareholders have approved the company's acquisition by a consortium led by executives Robert A. Ortenzio and Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe (WCAS). The deal, supported by a significant majority of outstanding shares, is expected to close by mid-2026, subject to customary closing conditions and regulatory approvals. The transaction signals continuity with management involvement and impacts the company's future direction and share value.
Select Medical Holdings Corporation announced that its shareholders have officially approved the tender offer initiated by a consortium composed of company executives Robert A. Ortenzio, Martin F. Jackson, and the private equity firm Welsh, Carson, Anders
Select Medical Holdings Corporation shareholders have approved a tender offer from a consortium including company executives Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS). This approval signifies a move towards privatization for the healthcare service provider, leading to its delisting from the public market after the transaction is finalized.
Press Release: Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical Holdings Corporation announced that its stockholders have approved the previously announced acquisition of the company by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and affiliates of Welsh, Carson, Anderson & Stowe. The merger is expected to close on or about December 27, 2012, subject to customary closing conditions. Upon completion, Select Medical will become a privately held company.
Select Medical (SEM) stockholders clear go-private merger led by insiders and WCAS
Select Medical Holdings Corporation (SEM) stockholders have approved a go-private merger led by a consortium including insiders Robert A. Ortenzio, Martin F. Jackson, and WCAS. The merger proposal received substantial majority and unaffiliated stockholder approval at a special meeting on June 26, 2026. The company anticipates the merger to close in mid-2026, subject to remaining conditions and regulatory approvals.
Select Medical shareholders back buyout by Ortenzio, Jackson and WCAS
Select Medical (NYSE: SEM) stockholders have approved the previously announced merger agreement with a consortium led by Robert A. Ortenzio, Martin F. Jackson, and WCAS. The approval, supported by over 79.88% of outstanding shares and over 76.64% of unaffiliated shares, indicates strong shareholder backing for the go-private transaction. The closing of the merger is anticipated by mid-2026, subject to satisfaction of remaining terms and conditions outlined in the merger agreement.
Select Medical Holdings Corporation Actuals & Estimates (FWB:S24)
This article provides an overview of Select Medical Holdings Corporation (FWB:S24) financials, analyst estimates, and key stock performance metrics. It covers past earnings, revenue, dividends, and future earnings estimates, alongside historical stock prices and company employee count. The piece also includes a disclaimer that it is not investment advice.
Select Medical (SEM) AGM 2026 Summary
Select Medical (SEM) held its 2026 Annual General Meeting as a virtual audio webcast on June 26, 2026, where stockholders approved a merger agreement with Stallion Intermediate Corporation and an advisory vote on executive compensation related to the merger. The merger will result in Select Medical becoming a wholly-owned subsidiary of Stallion, with the official vote count to be filed on Form 8-K.
Select Medical Holdings Corporation(NYSE: SEM) dropped from Russell 2500 Value Index
Select Medical Holdings Corporation (NYSE: SEM) has been removed from the Russell 2500 Value Index. This news follows several other index removals for the company on the same day, including the Russell 3000E Value Benchmark and Russell 2000 Dynamic Index. The company operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics across the United States.
Select Medical Holdings Corporation(NYSE:SEM) dropped from Russell Small Cap Comp Value Index
Select Medical Holdings Corporation (NYSE:SEM) has been removed from the Russell Small Cap Comp Value Index, as reported by S&P Capital IQ on June 25, 2026. This news follows several other announcements on the same date indicating SEM's removal from various Russell indices, including the Russell 3000E Value Benchmark and Russell 2000 Dynamic Index. Select Medical operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics across the United States.
[8-K] SELECT MEDICAL HOLDINGS CORP Reports Material Event
SELECT MEDICAL HOLDINGS CORP (SEM) filed an 8-K report detailing a material event related to its previously announced acquisition by a consortium. The company is facing multiple lawsuits and demand letters from stockholders alleging that its definitive proxy statement omits or misrepresents material information regarding the merger. To address these claims and avoid delays, Select Medical has voluntarily released supplemental disclosures, which include additional details on fees paid to executives, background information on the merger, and revised financial analysis figures.
SEM: Buyout Scrutiny And New Hospital Venture Will Shape Future Outlook
Select Medical Holdings is facing scrutiny over a proposed $16.50 per share buyout, with several law firms investigating potential fiduciary duty issues as some investors believe the offer undervalues the company. Concurrently, Select Medical Corporation has entered a joint venture to build a new 50-bed inpatient rehabilitation hospital in Roanoke, Virginia, with construction set for spring 2026. The company's fair value remains unchanged at $16.50 per share, despite slight adjustments in discount rate and future P/E assumptions.
Are BCO, SEM, NATL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating The Brink's Company (BCO), Select Medical Holdings Corporation (SEM), and NCR Atleos Corporation (NATL) for potential violations of federal securities laws and breaches of fiduciary duties concerning their recent transactions. The firm is examining Brink's merger with NCR Atleos, Select Medical's sale to a consortium, and NCR Atleos's sale to The Brink's Company to ensure fair deals for shareholders. Halper Sadeh LLC represents investors and may seek increased consideration or additional disclosures on their behalf.
$SEM Stock Drop Reminder: Select Medical Announces $16.50 per share Acquisition – BFA Law’s Investigation into the Board is Ongoing
Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's (NYSE: SEM) board of directors for potential breaches of fiduciary duties related to the company's pending acquisition for $16.50 per share. The investigation centers on the merger terms, which allow co-founder Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and certain affiliated entities to "rollover" their holdings into the post-merger company, a privilege not extended to public stockholders. Shareholders are encouraged to contact BFA Law if they have concerns about the fairness of the merger and potential legal options.
Select Medical (SEM) Board Investigated for Breaching its Duties to Investors - Current Shareholders Urged to Protect Your Rights
Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's (NYSE:SEM) board of directors for potential breaches of fiduciary duties related to the company's pending sale for $16.50 per share. The investigation focuses on the merger's terms, which allow certain insiders to "rollover" their holdings into the post-merger company, an option not extended to public stockholders. Current shareholders are urged to seek information and explore their legal options regarding the fairness of the merger and public disclosures.
Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by the board members of Select Medical Holdings Corporation (NYSE: SEM) regarding its proposed take-private transaction. The firm is examining whether the board conducted a fair process to maximize shareholder value, as a consortium including company executives plans to acquire outstanding shares for $16.50 per share in cash, while rolling over their own equity. Shareholders who believe their investment is undervalued are encouraged to join the investigation.
Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by the board members of Select Medical Holdings Corporation (NYSE: SEM) concerning its proposed take-private transaction. The investigation focuses on whether the board maximized shareholder value and if minority shareholders are receiving fair consideration, as the company is being acquired by a consortium including its executive chairman, senior executive vice president, and Welsh, Carson, Anderson & Stowe for $16.50 per share. The consortium members are rolling over their equity instead of taking cash, and they collectively own about 11.8% of outstanding common stock.
Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by the board members of Select Medical Holdings Corporation (NYSE: SEM) concerning its proposed take-private transaction. A consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe plans to acquire all outstanding shares not already owned by the consortium for $16.50 per share in cash. The investigation aims to determine if the board conducted a fair process and if minority shareholders are receiving fair consideration for their shares.
$SEM Securities Notice: BFA Law Notifies Select Medical Shareholders the Pending Investigation into the $16.50 per share Acquisition
Bleichmar Fonti & Auld (BFA) Law is investigating Select Medical Holdings Corporation (NYSE: SEM) and its board of directors for potential breaches of fiduciary duties related to its impending acquisition for $16.50 per share. The investigation centers on the fairness of the merger, particularly as certain insiders are allowed to "rollover" their holdings while public shareholders are only offered cash. Shareholders are encouraged to contact BFA Law to explore their legal options.
SEM News | SELECT MEDICAL HOLDINGS CORP (NYSE:SEM)
This article provides recent news and analysis for Select Medical Holdings Corp (NYSE:SEM), including updates on Q1 and Q4 2025 earnings, ongoing investigations by several law firms regarding a proposed $16.50 per share shareholder buyout, and a recent joint venture to expand its rehab footprint. The current stock price for SEM is listed at $16.585.
$SEM Stock Notification: Current Shareholder of Select Medical? Contact BFA Law about its Ongoing Investigation into the Board Over $16.50 per share Acquisition
Bleichmar Fonti & Auld LLP has launched an investigation into Select Medical Holdings Corporation's (NYSE: SEM) board of directors for potential breaches of fiduciary duties related to the company's proposed acquisition for $16.50 per share. The investigation focuses on the merger agreement, where insiders are allowed to "rollover" their holdings into the post-merger company, a benefit not extended to public stockholders. Current shareholders are encouraged to contact BFA Law to explore their legal options regarding the fairness of the merger.
SELECT MEDICAL HOLDINGS CORPORATION INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Select Medical Holdings Corporation's Directors and Officers for Breach of Fiduciary Duties - SEM
Scott+Scott Attorneys at Law LLP is investigating Select Medical Holdings Corporation (NYSE: SEM) and its directors and officers for potential breaches of fiduciary duties. This investigation stems from the proposed buyout of Select Medical Holdings for $16.50 per share by a group including its CEO, an Executive Vice President, and a private equity firm, which the firm believes may have provided inadequate consideration to shareholders. Shareholders are encouraged to contact Scott+Scott to discuss their rights and the ongoing investigation.
SEM: Joint Venture And Governance Changes Will Shape Balanced Outlook
Select Medical Holdings (SEM) has seen its analyst price target adjusted to $16.50, though its fair value remains steady. This comes as the company announces a joint venture with Carilion Clinic to build a 50-bed inpatient rehabilitation hospital in Roanoke, Virginia, and shareholders approve changes to its Board of Directors' structure. Select Medical also maintained its 2026 revenue guidance between US$5.6 billion and US$5.8 billion.
SEM Stock Notification: Select Medical Board Investigated for Breaching its Duties to Investors Over $16.50 Acquisition Price
Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's (NYSE: SEM) board of directors and senior management for potential breaches of fiduciary duties related to the company's pending $16.50 per share acquisition. The investigation focuses on the fairness of the merger, particularly as certain insiders are allowed to "rollover" their holdings while public shareholders are not. Shareholders are encouraged to seek additional information regarding their legal options.
SEM Legal Claims: The Select Medical Board may have
Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's board of directors and senior management for potential breaches of fiduciary duties related to the company's pending sale for $16.50 per share. The investigation focuses on the merger's fairness, particularly because Select Medical's co-founder, a senior executive, and a private equity firm with historical ties to a director are acquiring the company and rolling over their shares, while public stockholders are only offered cash. Shareholders are encouraged to contact BFA Law if they believe they have legal options.
